Showing 1-10 of 1540 results for "".
The Importance of Diversity in Clinical Trials
https://practicaldermatology.com/issues/april-2025/the-importance-of-diversity-in-clinical-trials/35606/The disproportionate representation of certain segments of the population in clinical trials is no secret, and research has shown that psoriasis studies are the least racially diverse of all dermatology studies in the US.DWTV Extra: Image-Guided SRT Consensus
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-image-guided-srt-consensus/35744/Jacob Scott, MD, chairman of the Dermatology Association of Radiation Therapy (DART), discusses an expert panel's recommendations on the role of image-guided superficial radiation therapy in the treatment of non melanoma skin cancer, which were published in an article titled "The Role of Image-GuideMaximizing Valuation and Outcomes for Practice Owners: A Conversation with Dana Jacoby
https://practicaldermatology.com/topics/practice-management/maximizing-valuation-and-outcomes-for-practice-owners-a-conversation-with-dana-jacoby/29889/Contributor Clint Bundy recently interviewed Dana Jacoby, President and CEO of Vector Medical Group, an operational and strategic consulting firm focused on the healthcare sector, to discuss building value in a dermatology and aesthetics practice and optimal ways to achieve full value for that businPatient Perspectives on Unmet Needs in Topical Psoriasis Therapy
https://practicaldermatology.com/issues/january-february-2025/patient-perspectives-on-unmet-needs-in-topical-psoriasis-therapy/32972/Despite the advantages of topical treatment, nonadherence (including overuse and underuse) affects up to 50% of patients, and therapy overuse is often incited by the desire for rapid clearance, ineffectiveness, and unclear instructions.- Carolyn I. Jacob, MDhttps://practicaldermatology.com/profiles/carolyn-i-jacob-md/LqN4Ro/
- Dr. Jacob Chacko Joins Bonti's Board of Directorshttps://practicaldermatology.com/news/dr-jacob-chacko-joins-bontis-board-of-directors/2457893/Jacob Chacko, MD has joined Bonti’s Board of Directors. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Communications
- Study: Test Improves the Risk Stratification of Patients with Stage I Melanomahttps://practicaldermatology.com/news/study-finds-decisiondx-melanoma-significantly-improves-the-risk-stratification-of-patients-with-stage-i-melanoma-compared-to-american-joint-committee-on-cancer-8th-edition-staging/2462252/Results from a recent study showed the potential of a 31-gene expression profile (31-GEP) test in improving the prognosis for patients diagnosed with stage I cutaneous melanoma. Despite being considered at low risk for metastasis or melanoma-specific death, patients with stage I cutaneous
- Medicis Announces Winners of First Annual I Acanya Succeed Scholarship Programhttps://practicaldermatology.com/news/20131007-medicis_announces_winners_of_first_annual_i_acanya_succeed_scholarship_program/2459442/Medics, a division of Valeant Pharmaceuticals North America LLC, recently announced the winners of its first I Acanya Succeed scholarship program, an education-based initiative that provides scholarships to college students who h
- BioFactura Starts Phase I Study of BFI-751, a Stelara Biosimilarhttps://practicaldermatology.com/news/biofactura-starts-phase-i-study-of-bfi-751-a-stelara-biosimilar/2460811/BioFactura is set to begin a pivotal pharmacokinetics Phase 1 clinical trial for its Ustekinumab biosimilar BFI-751. The first-in-human Phase I study will assess the effects on healthy human volunteers compared to the biologic medicine, Stelara. This is the first time BFI-751 has been a
- Phase I Trial for Implantable Melanoma Vaccine Beginshttps://practicaldermatology.com/news/20130910-phase_i_trial_for_implantable_melanoma_vaccine_begins/2459466/
- Prev
- Next